Levact (Bendamustine Hydrochloride)

Bendamustine is an alkylating agent that binds covalently to DNA, creating cross‑links that block replication and transcription. This interference halts cell division and triggers apoptosis, especially in rapidly proliferating malignant lymphocytes, thereby reducing tumor burden.

The dose of Levact is individualized by the prescribing oncologist based on factors such as the patient’s body surface area, disease stage, prior therapies, and laboratory parameters. No fixed regimen can be stated; the prescriber sets the appropriate dosing schedule.

Bendamustine is classified as contraindicated in pregnancy because it can cause fetal harm. It is also not recommended during breastfeeding, as it may be excreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception during treatment and for a defined period afterward.

To order Levact, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Levact (bendamustine) offers a dual mechanism of alkylation and antimetabolite activity, which can provide efficacy in patients who have relapsed after or are unsuitable for more intensive regimens such as CHOP or fludarabine‑based therapies. Its safety profile includes notable myelosuppression, but it is generally well‑tolerated compared with some high‑dose alkylators.

Levact should be stored at 2‑8 °C in a refrigerator, protected from light. The vials must not be frozen or shaken. During handling, use aseptic technique, keep the product in its original packaging until use, and discard any solution that appears discolored or particulate.

Levact is given as an intravenous infusion, typically over 30–60 minutes, under the supervision of qualified healthcare professionals. The infusion rate and schedule are determined by the treating physician, and patients are monitored for vital signs and adverse reactions during and after the administration.

The most serious risks include severe myelosuppression leading to infections, bleeding, or anemia; pulmonary toxicity such as interstitial pneumonitis; secondary malignancies like therapy‑related myelodysplastic syndrome; and rare but life‑threatening hypersensitivity reactions. Prompt medical evaluation is essential if these events occur.

Levact is contraindicated in patients with known hypersensitivity to bendamustine or any component of the formulation. It should also be avoided in individuals with uncontrolled active infections, severe organ dysfunction that precludes safe administration, and in pregnant or breastfeeding women unless the benefits outweigh the risks.